

**FEMOROPOPLITEAL DISEASE
INCIDENCE OF RESTENOSIS
AFTER ENDOVASCULAR REVASCULARIZATION
AND REVIEW OF COST-EFFECTIVENESS ANALYSES**

Mary L. Yost
404-520-6652
THE SAGE GROUP

THE SAGE GROUP, LLC
RESEARCH AND CONSULTING
23 Ridge Rd
Beaufort SC 29907

Copyright Pending
2020

All rights reserved, including the right of reproduction
in whole or in part in any form.

Table of Contents

SUMMARY	6
CONCLUSIONS	6
Incidence of Femoropopliteal Restenosis in Clinical Trials and Registries	6
Long-Term Restenosis Rates	7
Lesion Length Impacts Restenosis and Bailout Stenting Rates.....	7
Higher Incidence of Restenosis	7
Lesion Length Independently Predicts Restenosis	8
Bailout Stenting Increases in Long Lesions.....	8
Restenosis in Real-World Studies.....	8
Critical Limb Ischemia and Restenosis.....	8
Multiple Devices May Reduce Restenosis	9
Multiple Devices Increase Costs.....	9
Bailout Stenting Adds to Costs in Drug-Coated Balloon Interventions	9
Cost-Effectiveness	10
U.S. Costs of Femoropopliteal Restenosis.....	10
INTRODUCTION.....	11
DEFINITIONS	11
Restenosis Defined as Target Lesion Revascularization	12
COSTS	12
Primarily United States Costs	12
FEMOROPOPLITEAL DISEASE RESTENOSIS AFTER PERCUTANEOUS	
TRANSLUMINAL ANGIOPLASTY (PTA).....	12
Target Lesion Revascularization Rates in Clinical Trials and Registries.....	12
Limitations	14
Pooled Target Lesion Revascularization Rates.....	15
FEMOROPOPLITEAL DISEASE RESTENOSIS AFTER BARE METAL	
STENT (BMS) IMPLANTATION	15
Concerns About Femoropopliteal Stenting.....	15
Target Lesion Revascularization Rates in Clinical Trials and Registries.....	15
Bare Metal Stent Restenosis Rates Affected by Lesion Length and Other Factors..	17
Stent Design Impacts TLR.....	17
Limitations	17
Pooled Target Lesion Revascularization Rates.....	18
RESTENOSIS AFTER FEMOROPOPLITEAL DRUG-ELUTING STENT (DES)	
IMPLANTATION.....	19
Limitations	20
Pooled Target Lesion Revascularization Rates.....	21
RESTENOSIS AFTER FEMOROPOPLITEAL TREATMENT WITH	
DRUG- COATED BALLOON (DCB)	21
Limitations in Direct Comparisons of DCB Devices	23
Pooled Target Lesion Revascularization Rate	24

RESTENOSIS AFTER FEMOROPOPLITEAL TREATMENT WITH ATHERECTOMY	24
LONGER TERM RESTENOSIS RATES.....	25
Restenosis Rates Continue to Increase Through 10 Years After Treatment with Percutaneous Transluminal Angioplasty	27
LONG LESIONS	27
Target Lesion Revascularization Rates in Clinical Trials and Registries.....	27
Primary Patency (PP).....	29
Limitations	29
Target Lesion Revascularization Increases with Lesion Length	29
Bailout Stenting Generally Increases with Lesion Length and Calcification	30
REAL-WORLD STUDIES	31
Critical Limb Ischemia	32
Is Restenosis Higher in Critical Limb Ischemia Patients than in Intermittent Claudication Patients?.....	33
Does Critical Limb Ischemia Predict Restenosis?	33
MULTIPLE DEVICES EMPLOYED IN REAL-WORLD ENDOVASCULAR PROCEDURES	34
Multiple Devices May Reduce Restenosis	34
Multiple Devices Increase Cost	34
Bailout Stenting Adds to the Cost of Drug-Coated Balloon Treatment	35
COST-EFFECTIVENESS ANALYSIS	36
Limitations	36
UNITED STATES FEMOROPOPLITEAL COST-EFFECTIVENESS STUDIES	37
Summary	37
Economic Analysis of Endovascular Interventions for Femoropopliteal Disease.....	37
Model Inputs	38
Drug-Coated Balloon—The Least Expensive Treatment Strategy	38
Number Needed to Treat.....	39
Sensitivity Analysis	40
IN.PACT SFA II Cost-Effectiveness Analysis	40
Actual Costs Slightly Lower for DCB Treatment.....	40
Model Inputs	41
DCB More Cost-Effective	42
Sensitivity Analysis	42
Cost-Effectiveness Analysis of Drug-Coated Therapies in the Superficial Femoral Artery	42
Model Inputs	43
DCB Most Cost-Effective.....	44
Sensitivity Analysis	45

COST OF FEMOROPOPLITEAL RESTENOSIS AFTER TREATMENT WITH PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY	45
UNITED KINGDOM FEMOROPOPLITEAL COST-EFFECTIVENESS STUDIES	45
Economic Analysis of Endovascular Drug-Eluting Treatments for Femoropopliteal Disease	46
Model Inputs	46
PTA with Bailout Stenting—The Least Expensive Treatment Strategy	47
Cost-Effectiveness of Superficial Femoral Artery Endovascular Interventions in the United Kingdom.....	48
Model Inputs	48
GERMAN FEMOROPOPLITEAL COST-EFFECTIVENESS STUDIES	49
Economic Analysis of Endovascular Interventions for Femoropopliteal Disease-Germany.....	49
Model Inputs	49
Drug-Coated Balloon—The Least Expensive Treatment Strategy	50
CONSEQUENT Study—Drug-Coated Balloon More Cost-Effective	50
REFERENCES.....	52
APPENDIX I: ACRONYMS FOR CLINICAL TRIALS AND REGESTRIES	65
INDEX OF TABLES	70
CONTACT INFORMATION.....	72

CONTACT INFORMATION

Mary L. Yost
President
Telephone (404) 520-6652
yost@thesagegroup.us